Lonza expandiert in Visp
Published: Tuesday, Nov 12th 2024, 08:40
Retour au fil d'actualité
The pharmaceutical contract manufacturer Lonza plans to further expand production in Visp. The expansion envisages the construction of two additional production lines for the manufacture of various bioconjugates, each with a capacity of 1200 liters on a total area of 2000 square meters.
The investments in the new facilities and the corresponding infrastructure are intended to increase production capacities in order to meet the increasing demand from customers, Lonza announced on Tuesday. The new production lines are scheduled to commence operations in 2028 and create around 200 new jobs.
Lonza is currently increasing its production capacity at various locations. For example, the expansion of a facility in Basel was recently completed, and in September Lonza received the green light from the regulatory authority Swissmedic for a new multi-product facility, also in Visp. And in the USA, the company is currently expanding a production facility for endotoxin tests at the Walkersville site in the state of Maryland.
©Keystone/SDA
French 
English 
German 
Spanish 
Arabic